团队探索脂蛋白和干细胞在糖尿病等代谢疾病、心血管病的作用机制；冠心病、糖尿病血管并发症的关键生物标志物和干预靶点。从临床关键科学问题出发，流行病、临床医学课题研究（如课题设计、数据库建立和分析）与基础相结合的研究模式。具有流行病研究基础，建立糖尿病和普通人群数据库，与比利时高血压、心血管流行病学中心合作，开展中国、比利时人群队列的流行病学研究。

·       国家自然科学基金面上项目（2021年1月-2024年12月，#82070841, 56万元）：α-酮戊二酸通过OXGR1调控造血干/前体细胞增殖促进动脉粥样硬化的机制，主持 在研

·       国家自然科学基金面上项目(2017年1月 – 2020年12月，#81670765，69万元)：类血管生成因子4对2型糖尿病肾小球病变的作用和调控机制，主持 结题

·      国家自然科学基金面上项目(2015年1月 – 2018年12月，#81470566，73万元)：HDL通过SR-BI调节造血干细胞抑制动脉粥样硬化的作用和机制研究，主持 结题

·      国家自然科学基金面上项目(2015年1月 – 2018年12月)：拟人化Herg基因突变及敲除的糖尿病动物模型的建立，参与。

·     北京市科技计划项目-临床特色诊疗技术研究与转化应用（2020年9月– 2023年9月，Z201100005520062，20万元）：基于单细胞测序筛选新冠肺炎实变的治疗靶点的研究，主持 在研

·     北京市科技计划项目（2020年9月– 2022年3月，Z201100007920017，36万元）：COVID-19患者免疫应答规律和机制研究，主持 结题

·     北京市2016年留学人员优秀项目：造血干细胞作为冠心病独立危险因子的研究，主持 结题

·      国家自然科学基金面上项目（2021年1月-2024年12月，#82070841,56万元）：α-酮戊二酸通过OXGR1调控造血干/前体细胞增殖促进动脉粥样硬化的机制，主持

·      国家自然科学基金面上项目(2017年1月– 2020年12月，#81670765，69万元)：类血管生成因子4对2型糖尿病肾小球病变的作用和调控机制，主持。

·   国家自然科学基金面上项目(2015年1月– 2018年12月，#81470566，73万元)：HDL通过SR-BI调节造血干细胞抑制动脉粥样硬化的作用和机制研究，主持。

·   国家自然科学基金面上项目(2015年1月– 2018年12月)：拟人化Herg基因突变及敲除的糖尿病动物模型的建立，参与。

·   北京市科技计划项目-临床特色诊疗技术研究与转化应用（2020年9月–2023年9月，Z201100005520062，20万元）：基于单细胞测序筛选新冠肺炎实变的治疗靶点的研究，主持。

·   北京市科技计划项目（2020年9月–2022年3月，Z201100007920017，36万元）：COVID-19患者免疫应答规律和机制研究，主持

1.      Yu Cao#, XiaoliWang#, Siqi Li#, Yuan Dong, Yonghong Liu; Jing Li, Yanqing Zhao, Yingmei Feng*.Athird high dose of inactivated COVID-19 vaccine induces higher neutralizingantibodies in humans against the Delta and Omicron variants: a Randomized,Double-Blinded Clinical Trial. SciChina Life Sci. 2022. Accepted.

2.       Zhuolin Wang#, Yang Zhang#, Rirong Yang#, YujiaWang, Jiapei Guo, Ruya Sun, Yuan Zhou, Li Su*, Qing Ge*, Yinmei Feng*. Landscape of peripheral blood mononuclear cells andsoluble factors in severe COVID-19 patients with pulmonary fibrosisdevelopment. Frontiers in Immunology 2022. Accepted.

3.      XiaolingYu, XiangrongQi, YuCao, PeiyaoLi, LiLu, PingpingWang, YuchenFeng, JieYang, HuihuiWei, LixianGuo, MingyueSun, QiangLiu*, JingLv*, YingmeiFeng*. Three doses of an inactivation-based COVID-19 vaccineinduces cross-neutralizing immunity against the SARS CoV-2 Omicron variant. Emerg Microbes Infect. 2022 Feb 18;1-11. doi: 10.1080/22221751.2022.2044271. 

4.      Bin Su, Ruya Sun, Lili Zhang, JiayingZhang, Xia Feng, Zhenhuan Cao, Wei Hou, Xianghua Guo, Qing Ge, Qinghua Cui,Yuan Zhou, Yingmin Ma, Ronghua Jin, Yingmei Feng*. Single-cell RNAsequencing-based immunological feature analysis of a COVID-19 patient withrecurrent positive SARS-CoV-2 RNA. Chinese Medical Journal 2022; 135:0-0.Correspondence

5.      Luo X, Yan C,Zhang Y, Lu W, Feng Y*. Comment on"Effectiveness of dietetic intervention for people with type 2 diabetes: Ameta-analysis". ClinNutr. 2021 Dec;40(12):5660-5661. doi: 10.1016/j.clnu.2021.09.006. 

6.       Zhu R#, Yan T#, Feng Y#, LiuY#, Cao H, Peng G, Yang Y, Xu Z, Liu J, Hou W, Wang X, Li Z, Deng L, Wang S, LiJ, Han Q, Li H, Shan G, Cao Y, An X, Yan J, Zhang Z, Li H, Qu X, Zhu J, Zhou S,Wang J, Zhang F, Gao J, Jin R*, Xu D, Ma YQ*, Huang T, Peng S, Zheng Z,Stambler I, Gilson E, Lim LW, Moskalev A, Cano A, Chakrabarti S, Ulfhake B, SuH, Xu H, Xu S, Wei F, Brown-Borg HM, Min KJ, Ellison-Hughes G, Caruso C, Jin K,Zhao RC* Mesenchymal stem celltreatment improves outcome of  COVID-19 patients via multipleimmunomodulatory mechanisms. Cell Res. 2021Dec;31(12):1244-1262. doi: 10.1038/s41422-021-00573-y. 

7.       Xiao-Min Luo, Cen Yan, Yue-Jie Zhang,Ling-Jia Meng, Guo-Tao Lu, Ji-Ming Yin, Ying-Mei Feng*. Diabetic bonemarrow cell injection accelerated acute pancreatitis progression. Journal ofImmunological Research. 2021;2021:5123823.doi:10.1155/2021/5123823. 

8.       Ying-Mei Feng*, Lutgarde Thijs, Zhen-YuZhang, Esmee M. Bijnens, Wen-Yi Yang, Fang-Fei Wei,Bram G. Janssen, Tim S Nawrot, Jan A. Staessen. Glomerular function in relation to fineairborne particulate matter in a representative population sample. ScientificReports. 2021 Jul 19;11(1):14646.doi: 10.1038/s41598-021-94136-1. 

9.       Cao Y*,Yisimayi A, Bai Y, Huang W, Li X, Zhang Z, Yuan T, An R, Wang J, Xiao T, Du S,Ma W, Song L, Li Y, Li X, Song W, Wu J, Liu S, Li X, Zhang Y, Su B, Guo X, WeiY, Gao C, Zhang N, Zhang Y, Dou Y, Xu X, Shi R, Lu B, Jin R, Ma Y, Qin C*, Wang Y*, Feng Y*, Xiao J*, Xie XS*. Humoral immune response to circulating SARS-CoV-2 variants elicited byinactivated and RBD-subunit vaccines. Cell Res. 2021 Jul;31(7):732-741.doi: 10.1038/s41422-021-00514-9. 

10.    Zhao MM#, Yang WL#,Yang FY#, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM*,Wang YC*, Yang JK*. Cathepsin L plays a key role in SARS-CoV-2 infection inhumans and humanized mice and is a promising target for new drug development. Signal Transduction andTargeted Therapy. 2021. Mar 27;6(1):134. doi: 10.1038/s41392-021-00558-8. 

11.    Xiao Tang#, Ying-Mei Feng#, Ji-Xiang Ni#, Jia-Ying Zhang#, Li-Min Liu#, Ke Hu#, Xiu-Zhi Wu#, Ji-Xian Zhang, Jun-Wen Chen, Jian-Chu Zhang, Jian Su, Yu-Lei Li, Yang Zhao, Jiao Xie, Zhou Ding, Xin-Liang He, Wen Wang, Rong-Hua Jin, Huan-Zhong Shi, Bing Sun. Early Use of Corticosteroid May ProlongSARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration2021;100(2):116-126. doi: 10.1159/000512063.

12.    XiaominLuo#, Cen Yan#, Yingmei Feng*. Nanomedicine forTreatment of Diabetes-associated Cardiovascular Diseases and Fibrosis. AdvancedDrug Delivery Reviews 2021. Jan 5;S0169-409X(21)00004-1. 

13.    Xia Feng#, Jiming Yin#, Jiaying Zhang#, Yaling Hu, Yabo Ouyang, ShubinQiao, Hong Zhao, Tong Zhang, Xuemei Li, Lili Zhang, Jie Zhang, Ronghua Jin, YingmeiFeng*, Bin Su*，Longitudinal Profiling of AntibodyResponse in Patients with COVID-19 in a Tertiary Care Hospital in Beijing,China. Frontiers in Immunology. 2021 Mar 15;12:614436. 

14.    Wenmin Tian#, Nan Zhang#, Ronghua Jin#, Yingmei Feng#, Siyuan Wang, Shuaixin Gao, Ruqin Gao, Guizhen Wu, Di Tian, Wenjie Tan*, Yang Chen*, George FuGao*, Catherine CL Wong* . Immune suppression in the early stage ofCOVID-19 disease. Nat Commun. 2020.Nov 17;11(1):5859. doi: 10.1038/s41467-020-19706-9. 

15.   Bin Su#, Jiming Yin#, XingguangLin, Tiantian Zhang, Xiao Yao, Ying Xu, Yao Lu, Wenzhi Wang, KunLiu, Jie Zhang, Liangzhi Xie*, Ronghua Jin*, YingmeiFeng*. Quantificationof SARS-CoV-2 antigen in the blood of COVID-19 patients. Sci China Life Sci.2021 Jul;64(7):1193-1196. 

16.   HuZJ#, Xu J#, Yin JM#, Li L, Hou W, Zhang LL, Zhou Z, Yu Y, Li HJ, Feng YM*,Jin RH*, Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosisin COVID-19 Patients. Frontiers in Immunology. 2020;11:585647.

17.   Wang X#, Guo X#, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y*,Wang Q*. NeutralizingAntibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and ConvalescentPatients. Clin Infect Dis. 2020 Dec 17;71(10):2688-2694. doi: 10.1093/cid/ciaa721. 

18.   Yan C#, Thijs L#, Cao Y#,Trenson S, Zhang ZY, Janssens S, Staessen JA*, Feng YM*. Opportunities ofAntidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectivesfor Trial Design. Hypertension. 2020 Aug;76(2):420-431.

19.   LengZ#, Zhu R#, Hou W#, Feng Y#, Yang Y, Han Q, Shan G, Meng F, Du D, WangS, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, ZhaoY, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R*, Stambler I, Lim LW, Su H,Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K*,Zhao RC*. Transplantation of ACE2-MesenchymalStem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020Mar 9;11(2):216-228. 

20.   Yan C, Li YZ, Luo XM, Quan XJ*, Feng YM*. Roles of hematopoietic stem and progenitor cells in ischemiccardiovascular disease. Curr Stem CellRes Ther. 2020 Jan 29. doi: 10.2174/1574888X15666200130091858. 

21.   Zhao D#, Cao Y#, Yu CG, Yuan SS, Zhang N, Zhang YY, Staessen J, Feng YM*. The association of calcium channelblockers with β cell function in type 2 diabetic patients: a cross-sectionalstudy. J Clin Hypertens. 2019; 21(5):638-647. 

22.    Fu-Li Zhu1#, Ning Zhang#, Xiao-Juan Ma#, Jing Yang, Wei-Ping Sun,Yi-Qing Shen, Yu-Mei Wen, Sha-Sha Yuan,Dong Zhao, Hai-Bin Zhang, Ying-Mei Feng*. Circulating Hematopoietic Stem/Progenitor Cells AreAssociated with Coronary Stenoses in Patients with Coronary Heart Disease.Scientific Reports 2019 Feb 8;9(1):1680. 

23.   ZhangL#, Yan C#, Schouteden S, Ma X, Zhao D, Peter T, Verfaillie C, Feng YM*. The impact of integrin β2 ongranulocyte/macrophage progenitor proliferation. Stem Cells. 2019Mar;37(3):430-440. 

24.   FengYM. Gene therapy on the road. Curr GeneTher. 2019 ;19(1):6. Editorial.

25.   YanC, Quan XJ, Feng YM*. Nanomedicinefor gene delivery for the treatment of cardiovascular diseases. Current GeneTherapy. 2019;19(1):20-30. Invited review

26.   YuCG, Fu Y, Fang Y, Zhang N, Sun RX, Zhao D, FengYM*, Zhang BY*. Fighting type-2 diabetes: present and future perspectives. Current Medicinal Chemistry. 2019;26(10):1891-1907. 

27.   LiuS, Ke J, Zhang B, Yu C, FengY*, Zhao D*. A novel compound heterozugous variantof gene in a pedigree with Gitelman syndrome coexisted with thyroiddysfunction. Endocrine Practice. 2018 Oct2;24(10):889-893.

28.   Yu CG, Yuan SS, Yang LY, Ke J, Zhang LJ, Lang JN, ZhangDW, Zhao SZ, Zhao D, Feng YM*. Angiopoietin-like 3 is a PotentialBiomarker for Retinopathy in Type 2 Diabetic Patients. American Journal of Ophthalmology.2018 Jul;191:34-41. 

29.   Feng Y*,Thijs L, Zhang Z, Yang W, Huang Q, Wei F, Kuznetsova T, Jennings A, Delles C,Lennox R, Verhamme P, Dominiczak A, Staessen J*. Glomerular function inrelation to circulating adhesion molecules and inflammation markers in ageneral population. Nephrology Dialysis Transplantation 2018 Mar 1;33(3):426-435. 

30.   Yang L, Yu C, Wang X, Yuan S, Zhang L,Lang J, Zhao D*, Feng Y*.Angiopoietin-like protein 4 is a HDL component for HDL metabolism and functionin non-diabetic participants and type-2 diabetic patients. Journal of AmericanHeart Association. 2017 23;6(6).